

**Daftar Pustaka**

- [1] C. Drosten, W. Preiser, S. Günther, H. Schmitz, and H. W. Doerr, "Severeacute respiratory syndrome: Identification of the etiological agent," *TrendsMol. Med.*, vol. 9, no. 8, pp. 325–327, 2003, doi: 10.1016/S1471- 4914(03)00133-3.
- [2] A. Remuzzi and G. Remuzzi, "COVID-19 and Italy: what next?," *Lancet*, vol. 395, no. 10231, pp. 1225–1228, 2020, doi: 10.1016/S0140- 6736(20)30627-9.
- [3] H. Yang *et al.*, "Design of wide-spectrum inhibitors targeting coronavirusmain proteases," *PLoS Biol.*, vol. 3, no. 10, 2005, doi: 10.1371/journal.pbio.0030324.
- [4] W. W. C. Topley and S. G. S. Wilson, "Topley and Wilson's Microbiologyand Microbial Infections, 8 Volume Set, 10th Edition," *J. Infect.*, vol. 38, no. 2, p. 3500, 1999, [Online]. Available: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC501099/> [pdf:jclinpath00276-0077e.pdf].
- [5] Worldometers, "No Title," 2020. <https://www.worldometers.info/coronavirus/> (accessed Apr. 02, 2021).
- [6] S. A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, "Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining comparative validated multiple molecular modelling techniques," *J. Biomol. Struct. Dyn.*, vol. 36, no. 3, pp. 590–608, 2018, doi: 10.1080/07391102.2017.1288659.
- [7] S. Jain, S. A. Amin, N. Adhikari, T. Jha, and S. Gayen, "Good and bad molecular fingerprints for human rhinovirus 3C protease inhibition: identification, validation, and application in designing of new inhibitors through Monte Carlo-based QSAR study," *J. Biomol. Struct. Dyn.*, vol. 38,no. 1, pp. 66–77, 2020, doi: 10.1080/07391102.2019.1566093.
- [8] Y. Yang *et al.*, "The deadly coronaviruses: The 2003 SARS pandemic andthe 2020 novel coronavirus epidemic in China," *J. Autoimmun.*, vol. 109, no. February, p. 102434, 2020, doi: 10.1016/j.jaut.2020.102434.
- [9] L. Wang *et al.*, "Discovery of unsymmetrical aromatic disulfides as novelinhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study," *Eur. J. Med. Chem.*,vol. 137, pp. 450–461, 2017, doi: 10.1016/j.ejmech.2017.05.045.
- [10] A. Golbraikh and A. Tropsha, "Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test setselection," *J. Comput. Aided. Mol. Des.*, vol. 16, no. 5–6, pp. 357–369,2002, doi: 10.1023/A:1020869118689.
- [11] D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, "Docking and scoring in virtual screening for drug discovery: Methods and applications," *Nat. Rev. Drug Discov.*, vol. 3, no. 11, pp. 935–949, 2004, doi: 10.1038/nrd1549.
- [12] J. M. Halperin *et al.*, "Training Executive, Attention, and Motor Skills: AProof-of-Concept Study in Preschool Children With ADHD," *J. Atten. Disord.*, vol. 17, no. 8, pp. 711–721, 2013, doi: 10.1177/1087054711435681.
- [13] A. A. Toropov, A. P. Toropova, A. M. Veselinović, D. Leszczynska, and J.Leszczynski, "SARS-CoV Mpro inhibitory activity of aromatic disulfide compounds: QSAR model," *J. Biomol. Struct. Dyn.*, pp. 1–7, 2020, doi: 10.1080/07391102.2020.1818627.
- [14] L. Wang *et al.*, "Discovery of unsymmetrical aromatic disulfides as novelinhibitors of SARS-CoV main protease: Chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study," *Eur. J. Med. Chem.*,vol. 137, pp. 450–461, 2017, doi: 10.1016/j.ejmech.2017.05.045.
- [15] A. Gholamy, V. Kreinovich, and O. Kosheleva, "Why 70 / 30 or 80 / 20 Relation Between Training and Testing Sets : A Pedagogical Explanation," pp. 1–6.
- [16] S. Chtita *et al.*, "QSAR study of unsymmetrical aromatic disulfides as potent avian SARS-CoV main protease inhibitors using quantum chemicaldescriptors and statistical methods," *Chemom. Intell. Lab. Syst.*, vol. 210, no. February, 2021, doi: 10.1016/j.chemolab.2021.104266.
- [17] E. Pourbasheer, R. Aalizadeh, and M. R. Ganjali, "QSAR study of CK2 inhibitors by GA-MLR and GA-SVM methods," *Arab. J. Chem.*, vol. 12,no. 8, pp. 2141–2149, 2019, doi: 10.1016/j.arabjc.2014.12.021.
- [18] E. Pourbasheer, S. Vahdani, D. Malekzadeh, R. Aalizadeh, and A. Ebadi, "Qsar study of 17 $\beta$ -HSD3 inhibitors by genetic algorithm-support vector machine as a target receptor for the treatment of prostate cancer," *IranianJournal of Pharmaceutical Research*, vol. 16, no. 3. pp. 966–980, 2017, doi: 10.22037/ijpr.2017.2096.
- [19] E. Pourbasheer, S. Riahi, M. R. Ganjali, and P. Norouzi, "Application of genetic algorithm

- support vector machine (GA-SVM) for prediction of BK-channels activity,” *Eur. J. Med. Chem.*, vol. 44, no. 12, pp. 5023–5028, 2009, doi: 10.1016/j.ejmech.2009.09.006.
- [20] M. H. Fatemi and S. Gharaghani, “A novel QSAR model for prediction of apoptosis-inducing activity of 4-aryl-4-H-chromenes based on support vector machine,” *Bioorganic Med. Chem.*, vol. 15, no. 24, pp. 7746–7754, 2007, doi: 10.1016/j.bmc.2007.08.057.
  - [21] R. Burbidge, M. Trotter, B. Buxton, and S. Holden, “Drug design by machine learning: Support vector machines for pharmaceutical data analysis,” *Comput. Chem.*, vol. 26, no. 1, pp. 5–14, 2001, doi: 10.1016/S0097-8485(01)00094-8.
  - [22] S. Abe, “Support Vector Machines for Pattern Classification My ResearchHistory on NN , FS , and SVM,” *Sci. Technol.*
  - [23] F. Liu, C. Cao, and B. Cheng, “A quantitative structure-property relationship (QSPR) Study Of aliphatic alcohols by the method of dividingthe molecular structure into substructure,” *Int. J. Mol. Sci.*, vol. 12, no. 4, pp. 2448–2462, 2011, doi: 10.3390/ijms12042448.
  - [24] H. F. Azmi, K. M. Lhaksmana, and I. Kurniawan, “QSAR Study of Fusidic Acid Derivative as Anti-Malaria Agents by using Artificial Neural Network-Genetic Algorithm,” *2020 8th Int. Conf. Inf. Commun. Technol. ICoICT 2020*, pp. 3–6, 2020, doi: 10.1109/ICoICT49345.2020.9166158.
  - [25] F. Rahman, K. M. Lhaksmana, and I. Kurniawan, “Implementation of Simulated Annealing-Support Vector Machine on QSAR Study of Fusidic Acid Derivatives as Anti-Malarial Agent,” *6th Int. Conf. Interact. Digit. Media, ICIDM 2020*, no. Icidm, pp. 8–11, 2020, doi: 10.1109/ICIDM51048.2020.9339632.
  - [26] I. Kurniawan, M. S. Fareza, and P. Iswanto, “Comfa, molecular docking and molecular dynamics studies on cycloguanil analogues as potent antimalarial agents,” *Indones. J. Chem.*, vol. 21, no. 1, pp. 66–76, 2021, doi: 10.22146/ijc.52388.
  - [27] Y. Yuliana, “Corona virus diseases (Covid-19): Sebuah tinjauan literatur,” *Wellness Heal. Mag.*, vol. 2, no. 1, pp. 187–192, 2020, doi:10.30604/well.95212020.
  - [28] M. D. Christian Drosten, M.D., Stephan Günther, M.D., Wolfgang Preiser, M.D., Sylvie van der Werf, Ph.D., Hans-Reinhard Brodt, M.D., Stephan Becker, Ph.D., Holger Rabenau, Ph.D., Marcus Panning, M.D., Larissa Kolesnikova, Ph.D., Ron A.M. Fouchier, Ph.D., Annema, “Identification ofa Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome,” pp. 1967–1976, 2020.
  - [29] PDPI, “Panduan Praktik Klinis: Pneumonia COVID-19,” *J. Am. Pharm.Assoc.*, vol. 55, no. 5, pp. 1–67, 2020.
  - [30] J. Ivanov *et al.*, “Quantitative structure–activity relationship machine learning models and their applications for identifying viral 3Clpro- AndRDRP-targeting compounds as potential therapeutics for Covid-19 and related viral infections,” *ACS Omega*, vol. 5, no. 42, pp. 27344–27358, 2020, doi: 10.1021/acsomega.0c03682.
  - [31] J. H. Holland, *Adaption in natural and artificial systems*. Michigan: TheUniversity of Michigan Press, Ann Arbor, MI, 1975.
  - [32] C. HM, *Applications of artificial intelligence in chemistry*. Oxford: OxfordUniversity Press, Oxford, 1993.
  - [33] M. F. Asshiddiqi, Perbandingan Metode Decision Tree dan Support Vector Machine untuk Analisis Sentimen pada Instagram Mengenai Kinerja PSSI. Universitas Telkom, 2020. Accessed: Nov. 30, 2020. [Online]. Available: /home/catalog/id/163055/slug/perbandingan-metode-decision-tree-dansupport-vector-machine-untuk-analisis-sentimen-pada-instagram-mengenai-kinerja-pssi.html
  - [34] I. Aydin, M. Karakose, and E. Akin, “A multi-objective artificial immune algorithm for parameter optimization in support vector machine,” *Appl. SoftComput. J.*, vol. 11, no. 1, pp. 120–129, 2011, doi: 10.1016/j.asoc.2009.11.003.
  - [35] M. Ghifari, “Gif’s note Support Vector Machines: Penjelasan Matematisdan Intuitif,” pp. 1–13, 2021.
  - [36] Sahigara, F., Mansouri, K., Ballabio, D., Mauri, A., Consonni, V., and Todeschini, R., 2012, Comparison of different approaches to define the applicability domain of QSAR models, *Molecules*, 17 (5), 4791–4810.
  - [37] S. Yildirim, “Support Vector Machine - Explained,” 2020, [Online]. Available: <https://towardsdatascience.com/support-vector-machine-explained-8d75fe8738fd>.

